Current and future pharmacological therapies for NAFLD/NASH

Sumida, Yoshio; Yoneda, Masashi

doi:10.1007/s00535-017-1415-1

Public

Current and future pharmacological therapies for NAFLD/NASH

Published in Journal of Gastroenterology • Dec 15, 2017

Authors:

Yoshio Sumida

Masashi Yoneda

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy. The efficacy of vitamin E and pioglitazone has been established in nonalcoholic steatohepatitis (NASH), a progressive form of NAFLD. GLP-1RA and SGLT2 inhibitors, which a...

Subject

Medicine

Steatohepatitis

Pharmacology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!